<DOC>
	<DOCNO>NCT00246402</DOCNO>
	<brief_summary>The purpose study test whether chronic administration drug acipimox improve hyperlipidemia insulin sensitivity among HIV infect patient experience highly active antiretroviral therapy ( HAART ) associate metabolic disturbance .</brief_summary>
	<brief_title>Acipimox Improve Hyperlipidemia Insulin Sensitivity Associated With HIV</brief_title>
	<detailed_description>BACKGROUND : HIV infect patient treated HAART increase risk develop significant dyslipidemia , insulin resistance , abnormal pattern fat distribution . While exact mechanism responsible change know , increase evidence patient HIV infection fat redistribution increase basal rate lipolysis elevate circulate free fatty acid ( FFA ) . Patients HIV associate lipodystrophy increase FFA level correlate directly impair glucose metabolism triglyceride concentration . Furthermore , acute inhibition lipolysis patient HIV lipodystrophy insulin resistance result improvement insulin sensitivity . However , long-term administration lipolytic block agent evaluate patient population . Acipimox , nicotinic acid analogue potent inhibitor lipolysis , establish therapy dyslipidemia . In addition , effect lower circulate FFA , acute administration acipimox show improve insulin sensitivity population , include lean obese individual patient type II diabetes . This study test hypothesis chronic administration acipimox improve hyperlipidemia insulin sensitivity among HIV infect patient experience HAART associate metabolic disturbance . DESIGN NARRATIVE : The study 3-month double-blind placebo-controlled trial 250 mg acipimox three time daily 30 patient HAART lipodystrophy . The primary clinical endpoint study change fast triglyceride concentration , compare baseline value obtain 3 month acipimox placebo . Insulin sensitivity , important secondary endpoint , determine hyperinsulinemic euglycemic clamp study . Rates lipolysis fast state quantify 3-hour infusion stable isotope-labeled glycerol . Indirect calorimetry use assess change rest energy expenditure . Cross-sectional computed tomography ( CT ) image thigh abdomen allow measurement visceral subcutaneous fat area . Dual energy x-ray absorptiometry ( DEXA ) use determine whole body fat mass .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Acipimox</mesh_term>
	<criteria>Documented HIV infection Stable antiretroviral regimen great 3 month Hypertriglyceridemia ( fast triglyceride great 150mg/dl ) Evidence fat redistribution ( e.g. , increase abdominal cervical fat , and/or decrease subcutaneous fat face , arm , leg ) physical exam Current therapy lipid lower medication ( e.g. , fibrates , HMG CoA reductase inhibitor , resin ) treatment agent 3 month prior study entry Current use hormone replacement therapy , oral contraceptive woman , supraphysiologic testosterone therapy men Fasting triglyceride great 1000mg/dl Active alcohol substance abuse Active peptic ulcer disease History renal failure serum creatinine great 2.0 Serious opportunistic infection within 3 month prior study entry Hemoglobin le 11.0 mg/dl Elevated transaminase level ( AST ALT great 2.5x upper limit normal ) Previously diagnose diabetes mellitus patient receive current treatment diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>